RNAi Therapeutics Market Is At A CAGR Of 10.4% During The Forecast 2022-2032 | Quark Software , F. Hoffmann-La Roche , Rexahn Pharmaceuticals

The global RNAi Therapeutics Market was valued at USD 1.4 Billion in 2021 and it is anticipated to grow up to USD 3.8 Billion by 2031, at a CAGR of 10.4% during the forecast period.

Download Free Sample of Report - https://www.globalinsightservices.com/request-sample/GIS10510/?utm_id=1024

A brand-new class of drugs based on ribonucleic acid is known as RNA therapies (RNA). Target mRNA molecules are neutralized during the biological process known as RNA interference, and RNA molecules are then shown to impede gene expression or translation. Additionally, RNA interference (RNAi) is a group of short RNA-directed processes that inhibits the expression of genes in a sequentially-specific manner.

Market Trends and Drivers

Rising cases of chronic diseases

The rising rates of chronic diseases like cancer, cardiovascular conditions, and others will accelerate market expansion. The RNAi therapeutics market will be further fuelled by additional factors such as rising RNAi therapeutic approvals, advancements in the healthcare sector, rising R&D expenditures, and rising pharmaceutical company collaborations during the forecast period of 2023 to 2030.

Report Overview- https://www.globalinsightservices.com/reports/rnai-therapeutics-market

Increasing collaborative activities

The increasing collaboration activities between drug distribution companies and contract research organizations (CROs) contribute to the growth of the RNAi therapeutics market. Arrowhead Pharmaceuticals Inc and Horizon Therapeutics plc announced a global collaboration and licence agreement for ARO-XDH, a previously undisclosed discovery-stage investigational RNA interference (RNAi) therapeutic being developed by Arrowhead as a potential treatment for people with uncontrolled gout, on June 21, 2021. This collaboration with Horizon also represents an expansion of Arrowhead Pharmaceuticals' rapidly growing pipeline of investigational RNAi therapeutics based on the company's proprietary Targeted RNAi Molecule (TRiMTM) platform." In January 2016, Ionis Pharmaceuticals (previously Isis Pharmaceuticals) began a Phase-I study of ISIS-HBV-L Rx in collaboration with GSK Pharmaceuticals. This acquisition aims to treat Hepatitis B viral infection.

Major Players in the Global RNAi Therapeutics Market

The key players in the RNAi Therapeutics Market Quark Software Inc. (U.S.), F. Hoffmann-La Roche Ltd. (Switzerland), Rexahn Pharmaceuticals, Inc. (U.S.), Silence Therapeutics (U.K.), Arbutus Biopharma (U.S.), Benitec Biopharma (Australia), GSK plc (U.K.), OLIX PHARMACEUTICALS, INC. (South Korea), Sanofi (France), Alnylam Pharmaceuticals, Inc. (U.S.), Moderna Inc. (U.S.), Ionis Pharmaceuticals (U.S.), among others.

Get a customized scope to match your need, ask an expert - https://www.globalinsightservices.com/request-customization/GIS10510/?utm_id=1024

COVID-19 Impact

The COVID-19 pandemic is expected to play an emphasized part in propelling the growth of the RNAi Therapeutics market. Since the outbreak, the global payment industry has evolved rapidly owing to the rise in the use of digital payment methods among people as well as digital transformation worldwide. In line with this, the need for providing digital financial services to customers has increased among the banks, which thereby has created growth opportunities. Thus, creating the need for implementing encryption software to secure customers' data such as debit/credit numbers, and date of birth.

Global RNAi Therapeutics Market Segmentation

By Type

Small Interfering RNAS
Microrna

By Application

Oncology
Cardiovascular Diseases (CVDs)
Respiratory Disorders
Neurodegenerative Disorder
Genetic Disorders
Others

By Route of Administration

Pulmonary Delivery
Intravenous Injections
Intra-dermal Injections
Intraperitoneal Injections
Topical Delivery
Others

Buy Now - https://www.globalinsightservices.com/checkout/single_user/GIS10510/?utm_id=1024

With Global Insight Services, you receive:

10-year forecast to help you make strategic decisions
In-depth segmentation which can be customized as per your requirements
Free consultation with lead analyst of the report
Excel data pack included with all report purchases
Robust and transparent research methodology

About Global Insight Services:

Global Insight Services (GIS) is a leading multi-industry market research firm headquartered in Delaware, US. We are committed to providing our clients with highest quality data, analysis, and tools to meet all their market research needs. With GIS, you can be assured of the quality of the deliverables, robust & transparent research methodology, and superior service.

Contact Us:

Global Insight Services LLC
16192, Coastal Highway, Lewes DE 19958
E-mail: info@globalinsightservices.com
Phone: +1-833-761-1700
Website: https://www.globalinsightservices.com/

This release was published on openPR.